Published in J Immunol on February 01, 1985
Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun (2002) 2.44
Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci U S A (1986) 1.37
Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides. Biochem J (1990) 0.96
Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence. PLoS Pathog (2013) 0.90
Prediction from sequence comparisons of residues of factor H involved in the interaction with complement component C3b. Biochem J (1996) 0.87
Zebrafish complement factor H and its related genes: identification, evolution, and expression. Funct Integr Genomics (2010) 0.82
The rickettsial OmpB β-peptide of Rickettsia conorii is sufficient to facilitate factor H-mediated serum resistance. Infect Immun (2012) 0.80
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Complement. Annu Rev Biochem (1975) 6.00
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Complement. Annu Rev Biochem (1969) 3.51
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med (1969) 2.25
Genomic DNA differences between pathogenic and nonpathogenic Entamoeba histolytica. Proc Natl Acad Sci U S A (1989) 2.23
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Cytotoxic effects of leukocyres triggered by complement bound to target cells. Science (1969) 2.15
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
Complement: substitution of the terminal component in immune hemolysis by 1,10-phenanthroline. Science (1967) 2.11
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
The ninth component of human complement: purification and physicochemical characterization. J Immunol (1980) 2.09
C1q protein of human complement. Biochemistry (1972) 2.06
Primary structure of the 170-kDa surface lectin of pathogenic Entamoeba histolytica. Proc Natl Acad Sci U S A (1991) 2.05
Blood coagulation initiation by a complement-mediated pathway. J Exp Med (1971) 2.04
Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol (1976) 2.02
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
High mortality of infant bacteraemia clinically indistinguishable from severe malaria. QJM (2004) 2.00
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med (1981) 1.99
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med (1982) 1.92
The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8). J Exp Med (1976) 1.90
The alternative pathway of complement activation. Adv Immunol (1976) 1.87
Mechanism of action of factor D of the alternative complement pathway. J Exp Med (1978) 1.87
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet (1998) 1.84
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem (1975) 1.82
The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol (1978) 1.81
Immunochemical quantitation of the third, fourth and fifth components of human complement: concentrations in the serum of healthy adults. J Immunol (1967) 1.79
Physico-chemical characteristics of the third and fourth component of complement after dissociation from complement-cell complexes. Immunology (1967) 1.79
Immunofluorescent localization of the third and the fourth component of complement in synovial tissue from patients with rheumatoid arthritis. J Lab Clin Med (1967) 1.76
Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci U S A (1979) 1.76
Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol (1978) 1.76
The species Mycobacterium africanum in the light of new molecular markers. J Clin Microbiol (2004) 1.73
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry (1976) 1.71
The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol (1976) 1.67
Complement-immunoglobulin relation: deficiency of C'1q associated with impaired immunoglobulin G synthesis. Science (1969) 1.67
Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods (1984) 1.65
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
A fragment of the third component of human complement with anaphylatoxin activity. Biochemistry (1971) 1.64
A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med (1974) 1.63
Pore-forming peptide of pathogenic Entamoeba histolytica. Proc Natl Acad Sci U S A (1991) 1.63
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Connexin 26 R143W mutation associated with recessive nonsyndromic sensorineural deafness in Africa. N Engl J Med (1998) 1.55
C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med (1979) 1.55
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol (1983) 1.52
Species specificity of recognition by the alternative pathway of complement. J Immunol (1985) 1.49
C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J Immunol (1982) 1.48
Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement. Proc Natl Acad Sci U S A (1986) 1.48
Visualization of human C4b-binding protein and its complexes with vitamin K-dependent protein S and complement protein C4b. Proc Natl Acad Sci U S A (1983) 1.47
Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin. J Immunol (1977) 1.47
Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus. J Clin Invest (1972) 1.45